Cell Therapy Manufacturing for Reduced Heterogeneity and Enhanced Therapeutic Efficacy in Treatment of Acute Respiratory Distress Syndrome
Name
Krupczak-bkrupcza-phd-hst-2026-thesis.pdf
Size
26.92 MB
Format
Adobe PDF
Checksum (MD5)
b7747a67928a483a9dcada7c75cec9b7
Author(s)
Krupczak, Brandon
Advisor(s)
Van Vliet, Krystyn J.
Hammond, Paula T.
Date Issued
May 2026
Publisher
Massachusetts Institute of Technology
Abstract
Cell therapy—the use of living cells as medicine—is an emerging therapeutic modality with great potential to address unmet medical needs. Mesenchymal Stem/Stromal Cells (MSCs) represent a promising entrant to this field given their endogenous pharmacokinetic advantages, innate therapeutic characteristics, and suitability for allogeneic administration enabling manufacture at clinical scale. However, few MSC products have reached commercial stage owing to two key barriers: (1) phenotypic heterogeneity of the cellular product foments inconsistent batch-to-batch quality attributes, leading to inconsistent patient response and challenges identifying appropriate release criteria; (2) insufficient therapeutic efficacy in vivo, leaving critical patient needs unmet. This thesis work comprises our efforts to address these barriers to clinical translation using a unified microcarrier-microbioreactor manufacturing strategy that simultaneously reduces inter-batch phenotypic heterogeneity and putatively enhances aggregate therapeutic efficacy.
In order to guide our investigations, we identified an archetypal clinical indication to provide a defined treatment objective: Acute Respiratory Distress Syndrome (ARDS). ARDS is a critical (progression in hours to days), prevalent (> 200,000 annual cases in the US), and deadly indication (27%-46% mortality, depending on the grade of severity) that drew renewed focus during the COVID-19 Pandemic. While anti-viral medications have demonstrated utility in treatment of SARS-CoV-2-mediated ARDS, the majority of ARDS cases have non-viral etiologies for which there are no available pharmacological interventions to reduce mortality risk. MSCs are well-positioned to treat ARDS due to: (1) their native biodistribution to pulmonary tissue on systemic administration; (2) their immunomodulatory paracrine signaling ability; (3) the lack of effective conventional options for ARDS treatment. Nearly one hundred clinical trials have investigated the use of MSCs for ARDS treatment, though so far none have successfully translated to the clinic. There is a critical unmet need for enhanced MSC therapies with sufficient therapeutic consistency and potency to improve outcomes for patients.
Motivated by this goal, we explored a multifaceted strategy to produce enhanced MSCs, integrating advances in materials science, bioprocessing, biochemical regulation, and cell biology. First, we process engineered reliability improvements to our in-house gelatin microcarrier manufacture procedure, achieving production scale and reproducibility suitable for bioreactor-based cell manufacture. Next, we modified a commercially available microbioreactor system to enable anchorage-dependent MSC manufacture at benchtop scale, showcasing definitive improvements in resource consumption, cell yield, and putative therapeutic efficacy relative to conventional flask-based manufacturing approaches. We then explored iterative process parameter modifications to further enhance resultant MSC therapeutic potency and characterized improvements in therapeutic efficacy with multiple in vitro assays and models. Finally, we evaluated the impact of our microcarrier-microbioreactor manufacturing strategy on MSC heterogeneity, determining that our enhanced manufacturing approach yields a more consistent phenotypic product relative to the conventional gold-standard across multiple batches and unique donor identities.
Collectively, these results identify key bottlenecks restraining clinical translation of an important emerging modality with great potential to address unmet medical needs, suggest countermeasures to overcome these bottlenecks that show critical signs of early promise, and highlight mechanisms governing phenotypic heterogeneity with broad applicability to the larger scientific and clinical domains.
MIT Department
Harvard-MIT Program in Health Sciences and Technology
Terms of Use
In Copyright - Educational Use Permitted
Copyright retained by author(s)
Persistent DSpace Link